Verastem | VSTM - Cash And Equivalent


Verastem reported $137.71M in Cash and Equivalent for its fiscal quarter ending in September of 2025.





Cash And Equivalent Change Date
AbbVie USD 5.23B 400M Dec/2025
Alaunos Therapeutics USD 1.94M 941K Sep/2025
AstraZeneca USD 8.14B 1.08B Sep/2025
Curis USD 10.14M 10.14M Jun/2025
Cytokinetics USD 122.52M 102.95M Dec/2025
Gilead Sciences USD 7.33B 2.19B Sep/2025
Incyte USD 3.58B 650.78M Dec/2025
Laboratory Of America USD 532.3M 65.8M Dec/2025
Novartis USD 9.56B 2.9B Sep/2025
Pfizer USD 1.34B 295M Sep/2025
Roche Holding CHF 7.55B 579M Jun/2025
TG Therapeutics USD 199.51M 21.2M Dec/2025
Verastem USD 137.71M 20.14M Sep/2025